One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Growth ...
Nov 18, 2024
0
25
Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case report that signifies a potential breakthrough in the treatment of an aggressive type of prostate ...
Nov 5, 2024
0
72
Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular ...
Oct 23, 2024
0
31
For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer. But despite causing major disease, these slightly mutated proteins ...
Oct 22, 2024
0
65
Breast cancer is the most diagnosed cancer among U.S. women and the second leading cause of cancer death. Black women who develop breast cancer are around 40% more likely to die of the disease than white women, but it was ...
Sep 17, 2024
0
25
Research published in Frontiers of Medicine evaluates the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of disitamab vedotin (DV), a novel ...
Sep 4, 2024
0
21
There may be a way to slow the growth of endometrial cancer through targeted cancer cell therapy, according to new research from the University of Missouri School of Medicine.
Aug 21, 2024
0
33
One of the most innovative treatments for pediatric cancer today is a novel form of targeted immunotherapy that was recently developed and is now increasingly being applied to pediatric cancer treatment: chimeric antigen ...
Aug 5, 2024
0
50
The human epidermal growth factor receptor 2 (HER2) is a critical protein in the growth of cancer cells, and its expression level is a vital indicator of breast cancer aggressiveness. Traditionally, HER2 status is assessed ...
Jul 17, 2024
0
31
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
Jul 16, 2024
0
38
